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Abstract: The impact of rehabilitation-induced changes in 6-minute walk distance (6MWD) on 
the survival of patients with chronic obstructive pulmonary disease (COPD) has not been fully 
elucidated. This study sought to determine the association of baseline 6MWD and its changes 
after pulmonary rehabilitation (PR) with 5-year survival in patients with COPD. Patients who 
were referred to a 12-week outpatient PR program were followed up for 5 years postcompletion, 
and survival status was verified. Survival was analyzed according to four groups based upon 
initial 6MWD (6MWDi) and its changes (Δ6MWD) after PR (Group 1: 6MWDi $350 m and 
Δ6MWD $30 m; Group 2: 6MWDi $350 m and Δ6MWD ,30 m; Group 3: 6MWDi ,350 m 
and Δ6MWD $30 m; and Group 4: 6MWDi ,350 m and Δ6MWD ,30 m) via Kaplan–Meier 
analysis and log rank test. Cox regression was performed to identify possible confounders of 
mortality estimates. In total, 423 patients (with mean ± standard deviation of forced expiratory 
volume in the first second [FEV
1
] 43±16% predicted, age 65±8 years, and 6WMDi 381±134 m) 
underwent PR between 1999 and 2010. Survival rates decreased progressively from Group 1 to 
Group 4 (Group 1, 81%; Group 2, 69%; Group 3, 47%; Group 4, 27%; log rank test, P,0.05). 
6MWDi $350 m (hazard ratio [HR] 0.39 [95% confidence interval {CI} 0.30–0.50]) and 
Δ6MWD $30 m (HR 0.66 [95% CI 0.51–0.85]) were strongly and independently associated 
with survival. Compared with Group 1, mortality risks progressively increased in Group 2 (HR 
1.36 [95% CI 0.92–2.00]; not significant), Group 3 (HR 1.90 [95% CI 1.28–2.84]; P=0.001), and 
Group 4 (HR 3.28 [95% CI 2.02–5.33]; P,0.0001). Both poor 6MWD and lack of improvement 
>30 m after PR are associated with worse 5-year survival in patients with COPD.
Keywords: pulmonary disease, chronic obstructive, exercise training, mortality, 6-minute walk 
test, minimally important difference
Introduction
The 6-minute walk test (6MWT) is one of the most widely used assessments of exercise 
performance in chronic obstructive pulmonary disease (COPD), and a distance cov-
ered during the test (6-minute walk distance [6MWD]) is considered the primary test 
outcome.1 A considerable body of evidence demonstrates the importance of this test 
in clinical practice. Low 6MWD has consistently been associated with poor outcomes 
such as higher risks of respiratory and all-cause mortality in patients with COPD.2 
It has been shown that patients who walk less than 350 m have a high risk of mortality.3 
Twenty years ago, Gerardi et al reported that the distance covered in a 12MWT after 
exercise training is the strongest mortality predictor in patients with COPD.4 Increases 
in exercise capacity have also been demonstrated to improve the likelihood of 6-year 
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survival in patients with other diseases.5 To date, less is 
known about the impact of improved 6MWD on survival in 
respiratory patients.
Currently, pulmonary rehabilitation (PR) that includes 
high-intensity exercise training is the best strategy to improve 
exercise performance in patients with COPD.6 In addition to 
the well-known impact of PR on a wide range of outcomes 
(eg, exercise capacity, muscle force, health-related quality 
of life, and symptoms), PR has demonstrated some positive 
effects on the risk of hospitalisation7 and indirect associa-
tion with mortality by comparing the survival of completers 
with that of patients who declined or did not complete the 
intervention in the following 4 years.8
There is compelling evidence demonstrating that an 
increase in 6MWD of 30 m is clinically important.1,2 This 
improvement is typically achieved with PR;9 however, not 
all the patients benefit to the same extent.10 It is unclear 
whether an interaction exists between lack of improvements in 
6MWD and poor survival after PR. Outside the context of PR, 
deterioration of 6MWD .30 m over 1 year has been shown 
to increase the risk of hospitalizations and mortality.11 This 
further supports the use of this threshold in clinical practice.
The present study aimed to investigate the associations 
of 6MWD before PR and changes in 6MWD after PR with 
5-year survival in patients with COPD. 
Methods
Patients
Patients diagnosed with COPD12 and referred to the outpatient 
PR program of the University Hospital Leuven between 1999 
and 2010 were included in this retrospective study. Ethical 
approval was obtained from the hospital committee (S58488). 
The medical ethics committee of the University Hospital 
Leuven did not require informed consent to be obtained for 
this study, as it is seldom possible to obtain retrospective 
consents in studies investigating survival. Multiple diagnoses 
were allowed unless deemed to potentially preclude training 
completion or significantly affect prognosis (eg, awaiting lung 
transplantation, lung cancer). Patients who did not provide 
complete data regarding baseline 6MWD and/or 60-month 
survival status were excluded from the study. In order to inves-
tigate the effects on mortality of both initial 6MWD (6MWDi) 
and its change (Δ6MWD) after PR, patients were classified 
into one of four groups, defined a priori (Group 1: 6MWDi 
$350 m and Δ6MWD $30 m; Group 2: 6MWDi $350 
m and Δ6MWD ,30 m; Group 3: 6MWDi ,350 m and 
Δ6MWD $30 m; and Group 4: 6MWDi ,350 m and 
Δ6MWD ,30 m). The 350-m cutoff was chosen in this 
study as this has previously been shown to provide the best 
combination of sensitivity and specificity to detect mortality 
in patients with COPD,3 whereas the 30-m change cutoff 
represents the accepted minimally important difference for the 
6MWT.1 Patients who failed to complete 3 months of training 
(dropouts) were considered nonresponders and included in 
Group 2 or 4, according to their 6MWDi.
assessments
Before and after PR, all patients underwent routine screen-
ing that included complete lung function test,13 incremental 
cardiopulmonary cycling test,14,15 two 6MWTs (the high-
est distance covered),1 muscle force (dynamometry), and 
health-related quality of life (chronic respiratory disease 
questionnaire).16 Comorbidities were identified by using 
documented medication use at the initial assessment and were 
classified into four categories: cardiovascular, metabolic, 
musculoskeletal, and mental health. Medical records were 
inspected following PR completion to determine the timing 
and incidence of a first hospitalization.
Pr program
All the patients participated in a comprehensive, interdisciplin-
ary, 6-month PR program that included social, nutritional, and 
psychological support; optimization of prescription medica-
tions; and exercise training. The program was divided into 
two parts of equal duration (Months 1–3: intensive program; 
Months 4–6: maintenance program). The intensive program 
comprised of three sessions per week of high-intensity aerobic 
and resistive exercises for both the lower and upper limbs. 
Upon completion, patients were encouraged to continue for 
a further 3 months at a reduced frequency (two sessions per 
week) where training intensity and duration were not pro-
gressed further17 (ie, maintenance). Data from our center has 
shown the vast majority of training benefits typically occur 
during the initial intensive program.18 Therefore, for compa-
rability with many other PR programs, PR responses relative 
to the initial 3-month period are reported. Further information 
regarding characteristics and effectiveness of this PR program 
has been described in some previous studies.10,19
survival status
Survival status was determined at 60 months after PR 
completion by the inspection of electronic PR databases 
and hospital medical records. At our center in Leuven, 
patients underwent annual review with a maximal permit-
ted variation of 6 months. Therefore, any hospital visit (eg, 
outpatient appointment and admission) between Months 54 
and 60 was deemed indicative of 60 months of survival. If 
the status could not be verified, electronic obituary records 
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were examined. If no conclusive information was obtained, 
vital status was checked by contacting the patient’s general 
practitioner or relative. Patients with unclear survival status 
after this stage were excluded from the study.
statistical analysis
A complete description of the statistical analysis is provided 
in the Supplementary material. Statistical analysis was con-
ducted by using SAS Version 9.3 (SAS Institute Inc., Cary, 
NC, USA). Mortality curves were plotted using survival esti-
mates and were compared between groups by using log rank 
test and the Kaplan–Meier approach. A sensitivity analysis 
of potential confounders of mortality was conducted, which 
is further described in the Supplementary material. Cox 
regression analysis was used to adjust mortality estimates 
for potential confounders of survival (eg, age, quadriceps 
force,20 lung function,21 maximal exercise capacity,22 body 
mass index,23 and comorbidities24) and the additional impact 
of improved outcomes after PR (ie, cardiopulmonary exercise 
test, quadriceps force, health-related quality of life, and body 
mass index). Adjusted mortality estimates for Groups 2, 3, 
and 4 were then compared to Group 1. Significance of mor-
tality confounders was tested by using univariate regression 
analysis, and then, a multivariate model was used if statisti-
cally significant. Individually adjusted risks of mortality were 
estimated by calculating hazard ratios. Statistical significance 
was denoted by P,0.05.
Results
Figure 1 demonstrates the flowchart of patients’ inclusion 
in the present study. In total, 423 COPD patients who were 
referred to PR with known survival status at 60 months were 
included. Most of them (n=333, 78%) completed at least 
3 months of PR. Table 1 describes the baseline characteristics 
of the patients. Differences in exercise capacity (ie, 6MWD and 
cardiopulmonary cycling test) and muscle force were observed 
between patients who did or did not complete 3 months of 
training (P,0.01). Significantly better baseline lung function 
(P,0.001), muscle force (P,0.01), exercise capacity (6MWD 
and cardiopulmonary cycling test; P,0.001), and health-
related quality of life (P,0.01) were observed for patients 
with better baseline 6MWD (Groups 1 and 2) compared to 
patients with low baseline 6MWD (Groups 3 and 4).
rehabilitation responses
Significant positive effects were observed on measures of 
muscle force (11±18 Nm), 6MWD (45±73 m), incremental 
cycling test (10±15 watts), and health-related quality of life 
(chronic respiratory disease questionnaire, 16±12 points) after 
3 months of training in the entire cohort (P,0.05 for all). In 
total, 125 patients (60% of those who completed 3 months of 
training) improved 6MWD .30 m, and 243 improved chronic 
respiratory disease questionnaire (total score) by the minimally 
important difference of .10 points.25 Differences in training 
effects were observed between the four groups (Table 2). By 
definition, Groups 2 and 4 had less improvement in 6MWD 
than Groups 1 and 3. Despite the lack of improvements 
in exercise tolerance, Groups 2 and 4 experienced clinical 
improvements in health-related quality of life (P,0.01).
Post-Pr care
The majority of patients (83% of those who completed 
3 months of training) followed the maintenance program 
during 3–6 months. The proportion of attendees was high in 
Group 1 (93%) and Group 3 (84%), compared with 79% and 
61% in Groups 2 and 4, respectively (P,0.001). A small pro-
portion of attendees (n=54, 13%) were rereferred for a second 
course of PR at some point during the 60-month follow-up 
period. The incidence of having at least one respiratory-
related hospitalization during the year after beginning PR 
was significantly different between patients who completed 
the training and those who did not complete and increased 
from Group 1 to Group 4 (26%–56%; Table 1; P,0.001).
Mortality risk
The Kaplan–Meier analysis revealed significant differences 
in survival trajectories between all four groups (log rank 
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Figure 1 Flow chart of patients’ inclusion.
Abbreviations: COPD, chronic obstructive pulmonary disease; Pr, pulmonary 
rehabilitation.
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test, P,0.05), with survival rates progressively decreasing 
from Group 1 to Group 4 (Figure 2). The sensitivity analysis 
revealed no differences in responses attributable to the inclu-
sion of dropouts in Groups 2 and 4 or between the periods 
during which the patients were referred to PR (1999–2004 
or 2005–2010). Seven patients died (n=1 in Group 2 and n=6 
in Group 4) within the 3-month PR period. In the complete 
60-month follow-up, Groups 1 and 2 demonstrated lower 
mortality rates (19% and 31%, respectively) compared to 
Groups 3 and 4 (53% and 73%, respectively).
Univariate regression analysis confirmed commonly 
described mortality predictors that are significant in 
this cohort (Table 3). All a priori defined confounders 
significantly predicted mortality (P,0.001 for all). The 
values 6MWDi and Δ6MWD $30 m after PR were strong 
predictors of mortality (P,0.01 for both). Changes in other 
exercise outcomes after training significantly had an impact 
on mortality (P,0.01 for all).
Multivariate analysis revealed age, lung function, peak 
oxygen uptake, changes in quadriceps and cycling exercise 
outcomes, and both 6MWDi and Δ6MWD (Table 3) to be 
significantly predictive of mortality. Relative to Group 1 
(reference group), the risk of mortality at 60 months was 
significantly increased in all other groups (Table 4), increas-
ing from 1.36 times higher in Group 2 to 3.28 times higher 
in Group 4 (P,0.05 only for Groups 3 and 4).
Table 1 Baseline characteristics of subjects
Demographic characteristics All 
subjects 
Completed 3 months of PR Groups according to 6MWDi and ∆6MWD P-value
Yes No P-value 6MWDi $350 m 6MWDi ,350 m
∆$30 m; 
Group 1
∆,30 m; 
Group 2
∆$30 m; 
Group 3
∆,30 m; 
Group 4
number of patients 423 333 90 125 144 74 80
age (years) 65±8 66±8 65±8 0.7118 65±8 65±8 67±8 67±8 0.2380
Male sex, n (%) 335 (79) 265 (80) 70 (78) 0.7087 97 (77) 115 (80) 60 (81) 63 (79) 0.9400
BMI (kg⋅m-2) 25±6 25±5 25±7 0.7913 26±5 26±5 24±6 25±6 0.5474
lung function
FeV1 (% predicted) 43±16 43±15 44±19 0.8367 46±16 47±16 37±12*,† 37±16*,† ,0.0001
FeV1/FVC (%) 41±12 40±11 43±15 0.1643 42±11 42±11 37±11*,† 39±15 0.0066
FrC (% predicted) 154±37 154±37 152±38 0.5906 152±35 150±34 166±40*,† 153±39 0.0275
DlCO (% predicted) 48±17 48±18 48±18 0.8556 53±17 52±17 41±13*,† 40±17*,† ,0.0001
Peripheral muscle force
QF (nm) 100±38 102±37 92±38 0.0232 113±35 110±35 79±30*,† 80±35*,† ,0.0001
QF (% predicted) 69±26 69±23 66±36 0.4644 75±21 78±28 57±23*,† 58±25*,† ,0.0001
exercise capacity
Oxygen uptake (% predicted) 48±19 49±19 44±18 0.0245 53±18 51±18 40±18*,† 42±21*,† ,0.0001
Oxygen uptake (ml⋅kg⋅min-1) 14±4 14±4 13±4* 0.0038 16±4 15±5 12±4*,† 11±3*,† ,0.0001
Max workload (% predicted) 48±20 49±19 45±20 0.0892 55±19 53±18 37±18*,† 37±16*,† ,0.0001
6MWD (m) 381±134 395±129 328±138 ,0.0001 458±65 469±74 234±78*,† 230±84*,† ,0.0001
6MWD (% predicted) 59±21 61±20 52±22 ,0.0001 71±10 73±11 37±13*,† 37±14*,† ,0.0001
health-related quality of life
CrDQ dyspnea (points) 15±5 16±5 15±5 0.4908 16±5 16±5 14±5* 15±5 0.0161
CrDQ total score 78±17 78±17 76±17 0.1916 81±16 79±17 74±17* 73±16* 0.0026
Comorbidities
Cardiovascular (n, %) 313 (74) 246 (74) 67 (75) 0.8535 68 (85) 59 (79) 94 (66) 92 (74) 0.0124
Metabolic (n, %) 62 (15) 42 (13) 20 (23) 0.0209 12 (10) 17 (12) 14 (19) 19 (24) 0.0225
Musculoskeletal (n, %) 87 (21) 71 (22) 16 (18) 0.4730 23 (19) 17 (12) 26 (35) 21 (26) 0.0005
Mental health (n, %) 125 (30) 94 (28) 31 (35) 0.2387 35 (28) 34 (24) 27 (36) 29 (36) 0.1299
Hospital admissions in the first year
Time to first respiratory 
hospitalization (days)
129±97 99±88 138±99 0.0280 176±97 122±103 128±89 103±90* 0.0129
hospitalizations within Pr (n, %) 72 (17) 49 (14) 23 (25) 0.0152 8 (6) 24 (17) 16 (22) 24 (30) 0.0001
hospitalizations in the  
first year (n, %)
161 (38) 121 (36) 40 (44) 0.1598 32 (25) 48 (33) 36 (48) 45 (56) ,0.0001
Notes: Data shown as mean ± sD, n (%), or P-value. group 1: 6MWDi $350 m and Δ6MWD $30 m; group 2: 6MWDi $350 m and Δ6MWD ,30 m; group 3: 6MWDi 
,350 m and Δ6MWD $30 m; and group 4: 6MWDi ,350 m and Δ6MWD ,30 m. P-values of the four groups refer to one-way analysis of variance or Kruskal–Wallis test; 
*P,0.05 in post hoc test versus 1; †P,0.05 in post hoc test versus 2. Bold font denotes statistical significance (P,0.05).
Abbreviations: 6MWD, 6-minute walk distance; 6MWDi, initial 6MWD; BMI, body mass index; CrDQ, chronic respiratory disease questionnaire; Dlco, diffusion capacity 
for carbon monoxide; FeV1, forced expiratory volume in the first second; FRC, functional residual capacity; FVC, forced vital capacity; max, maximum; PR, pulmonary 
rehabilitation; QF, quadriceps force; sD, standard deviation.
International Journal of COPD 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2675
6MWD improvement and 5-year survival in COPD after Pr
Discussion
The present study confirms the importance of 6MWD as 
a prognostic indicator of mortality risk in patients with 
COPD and adds that patients who fail to improve at least 
30 m in 6MWD, as well as those with worse rehabilitation 
outcomes, have less chances of surviving a 5-year follow-up 
period. This supports an increasing body of evidence relating 
6MWD to mortality across a range of chronic respiratory 
conditions.3,26–28 The present study demonstrated that both 
the initial distance walked and the magnitude of its improve-
ment with PR were associated with survival. In patients who 
presented with increased risk of premature mortality due 
to greater impairment of functional exercise performance 
(6MWDi ,350 m), positive training response (improvement 
of 6MWD of at least 30 m) was associated with better likeli-
hood of 5-year survival to nearly twice as high.
The multivariate regression model, adjusted for confound-
ers, estimated that 6MWD .350 m was associated with lower 
risk of mortality (HR =0.39) than a lower 6MWD (Table 3). 
This finding is similar to the previous findings by Casanova 
et al who demonstrated that 350 m can provide the best sen-
sitivity and specificity of estimated mortality compared to 
both lower and higher values than this.3 Recently, an official 
systematic review by the European Respiratory Society and 
the American Thoracic Society on field tests proposed 317 m 
as a value discriminating high/low risk of mortality in 
patients with COPD.2 This threshold, despite being based 
on a large number of investigations, was not validated. 
The 350 m threshold was chosen, a priori, as it is used in 
the multidimensional body mass index, airflow obstruction, 
dyspnea, and exercise index, where any distance ,350 m 
increases mortality risk by a clinically significant margin.26
Importantly, it was identified that improved 6MWD with 
PR was associated with a significant reduction in mortality 
in a large set of patients referred to PR. This finding has high 
relevance for clinical practice, as a previous study reported 
effects of worse prognosis with deterioration of 6MWD.11,29 
Evidence from a previous study described the effect of PR 
Table 2 exercise training responses
Outcomes All subjects 
(n=333)
6MWDi $350 m 6MWDi ,350 m 
∆$30 m; 
Group 1 
(n=125)
∆,30 m; 
Group 2 
(n=98)
∆$30 m; 
Group 3 
(n=74)
∆,30 m; 
Group 4  
(n=36)
Peripheral muscle force
ΔQF (nm) 10 (0–22)* 11 (0–21)* 7 (-2–21)* 15 (4–29)*,‡ 7 (-2–15)*
ΔQF (% from baseline) 10 (0–25)* 8 (0–20)* 5 (-2–21)* 16 (6–46)*,‡ 11 (-2–24)*
exercise capacity
ΔOxygen uptake (% from baseline) 8 (-5–21)* 11 (-4–24)* 2 (-6–16)* 14 (0–24)*,‡ -4 (-17–0)*,†,§
ΔMax workload (% from baseline) 14 (0–30)* 16 (0–28)*,§ 11 (0–21)* 22 (0–50)*,†,‡ 0 (0–25)†,§
Δ6MWD (m) 43 (12–78)* 59 (45–91)* 0 (-26–17)† 86 (54–136)*,†,‡ -8 (-62–18)*,†,§
Δ6MWD (% from baseline) 10 (3–23)* 13 (9–21)* 0 (-5–3)† 39 (23–67)*,†,‡ -3 (-24–6)*,†,§
health-related quality of life
ΔCrDQ dyspnea 5 (2–8)* 6 (3–9)* 3 (1–8)*,† 6 (2–8)* 3 (0–6)*,†,§
ΔCrDQ total score 15 (8–24)* 17 (11–25)* 12 (4–22)*,† 16 (11–24)* 13 (2–22)*
Notes: Data shown as median (IQr). Data was only analyzed for subjects with data at both baseline and 3 months. group 1: 6MWDi $350 m and Δ6MWD $30 m; group 
2: 6MWDi $350 m and Δ6MWD ,30 m; group 3: 6MWDi ,350 m and Δ6MWD $30 m; and group 4: 6MWDi ,350 m and Δ6MWD ,30 m. *P,0.05 for changes from 
baseline. †Post hoc test versus 1; ‡post hoc test versus 2; §post hoc test versus 3.
Abbreviations: Δ, difference (3 months - baseline); 6MWD, 6-minute walk distance; 6MWDi, initial 6MWD; CrDQ, chronic respiratory disease questionnaire; IQr, 
interquartile range; max, maximum; QF, quadriceps force.
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Figure 2 Kaplan–Meier mortality curves for groups 1–4.
Notes: group 1: 6MWDi $350 m and Δ6MWD $30 m; group 2: 6MWDi $350 m 
and Δ6MWD ,30 m; group 3: 6MWDi ,350 m and Δ6MWD $30 m; and group 
4: 6MWDi ,350 m and Δ6MWD ,30 m.
Abbreviations: 6MWD, 6-minute walk distance; 6MWDi, initial 6MWD.
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on the body mass index, airflow obstruction, dyspnea, and 
exercise index and its associated positive impact on mortality. 
The present study showed that patients with stable moderate-
to-very severe disease who did not have positive outcomes 
with PR, applied in the usual clinical context (as part of 
evidence-based COPD management), increased their risk of 
premature death. Combination of 6MWDi and its changes 
revealed that such effect on mortality was more pronounced 
in the severely deconditioned patients (Groups 3 and 4).
The mortality effects observed at 60 months may be 
influenced by some other factors. The analyses identified 
several general and disease-related factors known to con-
found mortality estimates, such as body mass index, lung 
function, muscle force, and comorbidities. Of note, 21% 
of the patients referred to training did not complete the 
intervention. Although the sensitivity analysis excluding 
these patients from the model confirmed the lack of effect 
on mortality, it is possible that personal characteristics such 
as motivation to adhere to training play a role on survival. 
Although 6MWDi and changes in 6MWD were identified as 
strong independent predictors of mortality, the precise extent 
of causality cannot be confirmed. Furthermore, other exercise 
responses to the training were found to be related to mortality 
in the present cohort (Table 3). The observed improvements 
in oxygen uptake and quadriceps force are directly related to 
survival effects and reinforce the importance of monitoring 
responses after PR programs.
The Kaplan–Meier survival curves (Figure 2) revealed 
additional clinically important information regarding the 
sustained impact of PR on 6MWD change and potency of PR 
as a stimulus upon which to guide clinical decisions regard-
ing prognosis and patient care. In patients with consider-
able impairment of exercise performance (Groups 3 and 4), 
responses $30 m (Group 3) moderate survival trajectory during 
the subsequent year to levels that are almost identical to those 
in Groups 1 and 2 (6MWDi $350 m), before resuming a path 
closer to those in Group 4. The sensitivity analysis confirmed 
the effect observed in Groups 1 and 3 was not influenced by 
the potential negative effect of including patients who dropped 
out in Groups 2 and 4. Therefore, it is important that patients 
with profound functional limitation (Groups 3 and 4; 6MWDi 
,350 m) are not discouraged from attending PR. In contrast, 
this patient subgroup could be considered an important group to 
be referred to PR programs as the potential benefits of improv-
ing functional capacity with rehabilitation are high.
Table 3 Mortality risks estimates using univariate and multivariate regression analysis on possible mortality confounders
Confounders Univariate analysis; 
HR (95% CI)
P-value Multivariate analysis; 
adjusted HR (95% CI)
P-value
BMI ,21 kg⋅m-2 1.36 (1.02–1.80) 0.0327 – –
Presence of two or more comorbidities 1.24 (1.05–1.47) 0.0114 – –
age (per 5 years of increase) 1.16 (1.07–1.25) 0.0001 1.18 (1.06–1.31) 0.0017
Quadriceps force, as function of weight (per 10 units of increase) 0.97 (0.94–0.99) 0.0217 – –
FeV1, % predicted (per 10 units of increase) 0.82 (0.75–0.89) ,0.0001 – –
Oxygen uptake, % predicted (per 10 units of increase) 0.79 (0.73–0.85) ,0.0001 0.80 (0.72–0.89) 0.0010
DlCO, % predicted (per 10 units of increase) 0.78 (0.71–0.85) ,0.0001 – –
Change in FeV1, % predicted after training (per unit of increase) 0.98 (0.96–0.99) 0.0080 0.98 (0.96–0.99) 0.0258
Change in quadriceps force after training (per 10 units of increase) 0.90 (0.84–0.98) 0.0139 0.90 (0.82–0.99) 0.0326
Change in BMI after training, per unit of increase 0.88 (0.78–0.99) 0.0391 – –
Change in oxygen uptake, % predicted after training  
(per 10 units of increase)
0.85 (0.76–0.94) 0.0026 0.83 (0.70–0.98) ,0.0001
Change in Wmax after training (per 10 units of increase) 0.79 (0.70–0.88) ,0.0001 – –
Change in 6MWD $30 m 0.66 (0.51–0.85) 0.0013 0.68 (0.49–0.94) 0.0214
enrolling in the maintenance program (months 3–6) 0.62 (0.44–0.86) 0.0052 – –
Initial 6MWD $350 m 0.39 (0.30–0.50) ,0.0001 0.46 (0.32–0.65) ,0.0001
Notes: Only variables that remained in the model are reported in the multivariate regression analysis. Bold font denotes statistical significance (P,0.05). –, indicates that the 
variable was not included in the multivariate model.
Abbreviations: 6MWD, 6-minute walk distance; BMI, body mass index; CI, confidence interval; DLco, diffusion capacity for carbon monoxide; FeV1, forced expiratory 
volume in the first second; HR, hazard ratio; Wmax, maximal workload during cycling exercise test.
Table 4 Mortality risk estimates in the four groups adjusted by 
confounders
Adjusted risk compared to G1 HR adjusted (95% CI) P-value
g4: ,350 m and delta ,30 m 3.28 (2.02–5.33) ,0.0001
g3: ,350 m and delta $30 m 1.90 (1.28–2.84) 0.0016
g2: $350 m and delta ,30 m 1.36 (0.92–2.00) 0.1144
Notes: g1, group 1: 6MWDi $350 m and Δ6MWD $30 m; g2, group 2: 
6MWDi $350 m and Δ6MWD ,30 m; g3, group 3: 6MWDi ,350 m and 
Δ6MWD $30 m; g4, group 4: 6MWDi ,350 m and Δ6MWD ,30 m. Bold font 
denotes statistical significance (P,0.05).
Abbreviations: 6MWD, 6-minute walk distance; 6MWDi, initial 6MWD; CI, 
confidence interval; HR, hazard ratio.
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Limitations
The findings from this study should be considered in light 
of some possible limitations. The primary end point of this 
study (mortality) was verified by using a comprehensive and 
trustworthy database including patients’ medical history. 
When not available, the end point was searched on electronic 
obituaries or was obtained by contacting the patients’ general 
practitioners or relatives (increasing the chance of incorrectly 
retrieved date of death). Although such sources of informa-
tion can provide bias to the study, the authors excluded 
any doubtful survival status (only 5% of the sample). This 
approach, although limited, guaranteed the reliability of the 
presented results. This was a retrospective and observational 
study, and the results related to the Δ6MWD have not been 
prospectively confirmed with comprehensive monitoring 
of other factors that may affect mortality during follow-up. 
For example, it could be speculated that patients who are 
able to sustain improvements in exercise capacity for longer 
periods may have decreased mortality risks during follow-up. 
This could not be confirmed due to incomplete availability 
of 6MWD data in the yearly follow-up visits. Furthermore, 
frequency of exacerbations (hospitalized or nonhospitalized), 
changes to medications and comorbidities could all contribute 
to long-term outcomes. Although best attempts were made 
to control for as many potentially influential factors as pos-
sible in the present analysis, this was limited to data available 
within existing comprehensive databases. Data regarding the 
incidence of the first respiratory-related hospitalization, for 
example, were only accurately determined during the first 
year after beginning PR and did not distinguish between fre-
quent and infrequent exacerbator phenotypes. Nevertheless, 
it is important to note the association of lack of improved 
6MWD with worse survival in both functional exercise 
capacity classes (Groups 2 and 4). Identification of the pre-
cise mechanism(s) driving the interaction between lack of 
physiologic training response and decreased survival should 
be a priority of future investigations in this field.
Conclusion
The findings from this present study confirm the prognostic 
importance of the 6MWT in patients with stable COPD. Both 
poor 6MWD and lack of its improvement with PR (,30 m) 
were independently related to worse 5-year survival in 
patients with COPD referred to PR.
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Supplementary materials
Methods
statistical analysis
Statistical analyses were conducted with SAS Version 9.3 
(SAS Institute Inc., Cary, NC, USA). Data were described 
as mean ± standard deviation or median [interquartile range] 
according to data distribution. Data normality was assessed 
by Shapiro–Wilk test.
Data comparisons
Unpaired t-test and Mann–Whitney test were used to com-
pare baseline differences between subjects who did or did 
not complete the training. One-way analysis of variance 
and Kruskal–Wallis tests were used to compare differences 
between the four groups at both baseline and after training.
survival analysis
In order to verify survival estimates, a nonparametric 
survival method was used to plot Kaplan–Meier survival 
curves. Between-group differences were analyzed by using 
log rank test.
Cox regression analysis was used to adjust mortality 
estimates for potential confounders (eg, age, quadriceps 
force,1 lung function,2 maximal exercise capacity,3 body mass 
index,4 and comorbidities5). Additional impact on mortality 
by improving other training outcomes (ie, cycling exercise 
test, quadriceps force, health-related quality of life, and body 
mass index) was also investigated. Univariate regression 
analysis was used to identify the significance of aforemen-
tioned confounders. Statistically significant variables were 
added into a multivariate model. Individually adjusted risks 
of mortality were estimated by calculating hazard ratios.
sensitivity analysis on mortality estimates
In order to assure that no factors related to the group allo-
cation criteria or the long-term inclusion would interfere 
on the mortality estimates, two sensitivity analyses were 
conducted.
1. Removing “dropout” subjects from Groups 2 and 4. 
Patients who failed to complete the 3 months of exercise 
training were considered “drop-out” and were allocated 
into either the Group 2 (if initial values of 6MWD $350 m) 
or Group 4 (if initial values of 6MWD ,350 m).
2. Comparing mortality estimates between subjects referred 
to PR program in the first and the second half of the 
11 years of inclusion (1999–2010). In order to guarantee 
that possible differences in medical treatment during 
the entire follow-up would not interfere in the survival 
estimates, survival estimates between patients referred 
to the rehabilitation program between January 1999 and 
July 2004 (first half) and those referred between August 
2004 and July 2010 (second half) were compared.
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